Contact Info

102 Avenue Gaston Roussel
Batiment Pasteur Secteur 2169
93230 Romainville - France

56 Boulevard de la Mission Marchand - 92400 Courbevoie - France

Phone: +33 6 60 90 41 24

2019 – Sendai, Japan – EU-Japan Industrial Cooperation

Regulaxis is very proud to be the only French company selected by the EU-Japan Industrial Cooperation Center to be part of the European delegation !
Thank you also to Miyagi province officials and Jetro for receiving us and meeting top industrial companies in Sendai.

Dr. Matthieu Chareyre, our Executive Director of Industrial Operations, represented Regulaxis to this […]

May 30th, 2019|0 Comments

2019 – Milan, Italy – “Outsourcing in Clinical Trials Europe”

 

Regulaxis’ President and CEO Claude Carelli and the CSO Christelle Vêtu participated to the OCT conference in Europe, in Milan, Italy, on May 14-15.

May 14th, 2019|0 Comments

2019 – Toronto, Canada – OARSI World Congress on Osteoarthritis

REGULAXIS is at the 2019 OARSI conference in Toronto from 2nd-5th of May !
Doctor Christelle Vêtu, CSO and Strategic Business Advisor will present the latest results during the poster session : “Chimeric Peptide combining both Growth Hormone and Somatostatin Sequences (REG-O3) improves function and prevents cartilage degradation in rat model of Osteoarthritis” (POSTER #611).
Meet […]

May 2nd, 2019|0 Comments

2019 – Paris, France – ANRT – CLUB PME – ETI

Lors de la séance du 8 Avril du CLUB PME – ETI  Claude CARELLI, Président et CEO de Regulaxis a présenté son entreprise et son « business model ». Les membres du Club l’ont « challengé » pour qu’il récolte le fruit de ce «brainstorming » collectif.
Engagée dans la R&D, Regulaxis développe des molécules peptidiques […]

April 8th, 2019|0 Comments

2018 – Regulaxis moves to La Défense !

The offices of the Regulaxis Management Office are located at the feet of La Défense, the business district located in the Metropole du Grand Paris.

December 10th, 2018|0 Comments

2018 – Liège, Belgium – REG-O3, the innovative therapeutic treatment for Osteoarthritis will be tested in Liège ! Partnership between REGULAXIS and ARTIALIS.

Simoultaneous announcement in Paris, France and Liège, Belgium [June 25], 2018 :
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing the […]

June 15th, 2018|0 Comments

2018 – Liverpool, United Kingdom – OARSI World Congress on Osteoarthritis

REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress, to be held April 26-29, 2018 in Liverpool, UK.

April 26th, 2018|0 Comments

2018 – Macau, China – 14th World Congress of ICRS (International Cartilage Regeneration & Joint Preservation Society)

Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
ACCEPTED POSTER :
“REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis”
Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU
 

April 9th, 2018|0 Comments

2017 – REGULAXIS awarded from EU HORIZON 2020 PROGRAM !

Regulaxis is proud to announce to receive € 2.1m from EU Horizon 2020 SME instrument Phase 2 program for early gonarthrosis (OA) therapeutic drug regenerating cartilage !
 

May 1st, 2017|0 Comments

2016 – Romainville, France – BIOCITECHDAY

Dr. Claude Carelli, President and CEO of REGULAXIS, presented to BIOCITECHDAY the innovative molecule under development for the therapeutic treatment of knee osteoarthritis.

June 28th, 2016|0 Comments